Netupitant/Palonosetron Hydrochloride

Phase 1Small molecule

UUniversity of Rochester NCORP Research Base

Netupitant/Palonosetron Hydrochloride is one of 55 small molecule programs targeting Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CancerNot yet recruiting

CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

58 competitors in Cancer

#DrugCompanyPhaseTrials

Vemlidy

Gilead

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 3

Keytruda

Merck & Co.

Phase 2

4 4

Tecentriq

Roche

Phase 2

4 5

Afinitor

Novartis

Phase 2

3 6

Cotellic

Roche

Phase 2

3 7

Herceptin

Roche

Phase 2

2 8

Lenvima

Eisai

Phase 2

2 9

Verzenio

Eli Lilly

Phase 2

2 10

Stivarga

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Cancer

NCT07662200

Clinical

Trials by Indication[1]

Nausea and vomiting1 trial

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed·UUniversity of Rochester NCORP Research Base·Phase 3·NCT03367572·1,363 enrolled

Cancer1 trial

A Pilot Feasibility Study of a Steroid-Sparing Anti-Nausea and Vomiting Regimen With Netupitant/Palonosetron for Patients With Germ Cell Tumours Receiving Multi-Day Cisplatin-Based Chemotherapy at The Ottawa Hospital

Not yet recruiting·OOttawa Hospital Research Institute·Phase 1·NCT07662200·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Netupitant/Palonosetron Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Netupitant/Palonosetron Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Netupitant/Palonosetron Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Rochester NCORP Research Base company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Rochester NCORP Research Base

Netupitant/Palonosetron Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Nausea and vomiting1 trial

Cancer1 trial

References

Drug Info

Quick Facts

Related News